<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01084993</url>
  </required_header>
  <id_info>
    <org_study_id>EASY-B2B</org_study_id>
    <nct_id>NCT01084993</nct_id>
  </id_info>
  <brief_title>EArly Discharge After Transradial Stenting of CoronarY Arteries in High-Risk Patients of Bleeding</brief_title>
  <acronym>EASY-B2B</acronym>
  <official_title>EArly Discharge After Transradial Stenting of CoronarY Arteries in High-Risk Patients of Bleeding: Bivalirudin to Reduce Bleeding EASY-B2B Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE:

      Transradial coronary stenting is associated with less risk of access site complications and
      bleeding compared to femoral approach.

      Major bleeding post-PCI is a strong independent predictor of mortality and MACE. Depending of
      the antithrombotic regimen and access-site used, bleeding related to access-site represents
      50-80% of the cases. Whereas transradial approach minimizes the risks of access-site
      bleeding, it has no impact on non-access site bleeding.

      Peri-procedural anemia is also an independent predictor of mortality and MACE.

      With femoral approach, bivalirudin compared to heparin ± glycoproteins IIb-IIIa has been
      associated with a significant reduction in access-site and non-access site related bleeding.

      In a post-hoc analysis of patients treated by transradial approach in ACUITY, there was a
      trend for non-access site bleeding (organ bleeding) with bivalirudin compared to heparin ±
      glycoproteins IIb-IIIa.

      HYPOTHESES:

      In patients at high-risk of peri-procedural bleeding, bivalirudin ± glycoproteins IIb-IIIa
      reduces the risk of bleeding compared to heparin ± glycoproteins IIb-IIIa.

      In patients at high-risk of bleeding and undergoing transradial PCI, bivalirudin
      significantly reduces the incidence of non-access site bleeding and peri-procedural anemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      The primary objective is to compare the incidence of major bleeding and anemia 24h post-PCI
      in patients at high-risk of bleeding after transradial PCI with heparin or bivalirudin.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major bleeding and Mace</measure>
    <time_frame>24h post-PCI and Discharge</time_frame>
    <description>The primary end-points will be 1) the incidence of major bleeding (Replace-2 criteria) at hospital discharge and 2) the incidence of 24h post-PCI anemia (WHO criteria)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EFFICACY and SAFETY PARAMETERS</measure>
    <time_frame>30 days</time_frame>
    <description>The composite of death, MI (def 1 : Tn-t &gt; 0.1 and def 2 : CK-MB &gt; 30μg/l), urgent revascularization and major bleeding at 30 days post-PCI.
The incidence of ARC-defined stent thrombosis at 30 days. The incidence of access-site hematoma according to EASY scale. The incidence of radial artery occlusion at hospital discharge according to echo-doppler evaluation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Bivalirudin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard practice: 0.75mg/kg + infusion 1.75mg/kg/h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>70 U/kg or standard practice</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bivalirudin</intervention_name>
    <description>Standard practice: 0.75mg/kg + infusion 1.75mg/kg/h</description>
    <arm_group_label>Bivalirudin</arm_group_label>
    <other_name>Angiomax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>70 U/kg</description>
    <arm_group_label>Heparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least two of the following additional criteria

          -  At least 70 yrs old

          -  Female gender

          -  Diabetes

          -  Creatinine clearance &lt;60mL/min

          -  History of gastro-intestinal or other organ bleeding

          -  Baseline anemia

          -  Current treatment with glycoproteins IIb-IIIa inhibitors

        Exclusion Criteria:

          -  Intolerance or allergy to ASA, clopidogrel or ticlopidine precluding treatment for 12
             months

          -  Concurrent participation in other investigational study

          -  Femoral sheath (artery)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier F Bertrand, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IUCPQ</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier F Bertrand, MD, PhD</last_name>
    <phone>418-656-8711</phone>
    <email>olivier.bertrand@criucpq.ulaval.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michele Jadin, MSc</last_name>
    <phone>418-656-8711</phone>
    <phone_ext>3007</phone_ext>
    <email>michele.jadin@criucpq.ulaval.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Quebec Heart-Lung Institute</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Jadin, MSc</last_name>
      <phone>418-6568711</phone>
      <phone_ext>3007</phone_ext>
      <email>michele.jadin@crhl.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Olivier F Bertrand, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2010</study_first_submitted>
  <study_first_submitted_qc>March 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2010</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Laval University</investigator_affiliation>
    <investigator_full_name>Olivier F. Bertrand</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Coronary artery stenting, transradial, intracoronary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Bivalirudin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Hirudins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

